PF-Atlas › Mechanisms
IPF Mechanisms of Action (53)
The biological targets and pathways behind idiopathic pulmonary fibrosis therapies — PDE4B inhibition, LPA1 antagonism, TGF-β signaling, senescence and more. Each links to the drugs and trials that act on it.
- ANZCTR · 9 trials
- Senolytics · 3 trials
- China Registry · 2 trials
- PDE4B Inhibition · 2 trials
- Prostacyclin Analog · 2 trials
- AAV-TERT restores telomere length in AEC2s — addresses genetic root cause · 0 trials, 1 therapy
- Adoptive transfer of lung-resident memory T cells reverses established fibrosis · 0 trials, 1 therapy
- Anti-CTGF/CCN2 · 1 trial
- Applying proven liver fibrosis reversal mechanisms to lung — stellate cell parallels to myofibroblast · 0 trials, 1 therapy
- Autologous iPSC-AEC2s replace depleted stem cell pool in prepared niche · 0 trials, 1 therapy
- Autotaxin/LPA1 · 1 trial
- Base editing corrects genetic mutations causing lung disease without DNA double-strand breaks · 0 trials, 1 therapy
- BCL-2/BCL-XL inhibitor — more potent senolytic than D+Q · 0 trials, 1 therapy
- Blocks mechanosensing amplification loop — breaks stiffness-to-fibrosis cycle · 0 trials, 1 therapy
- Blocks SASP cytokine signaling (IL-6, IL-8) without killing senescent cells · 0 trials, 1 therapy
- CAR-T cells targeting uPAR (urokinase plasminogen activator receptor) on senescent cells — living drug senolytic · 0 trials, 1 therapy
- CRISPR Base Editing · 1 trial
- Dendritic Cell Immunotherapy · 1 trial
- Direct clearance of FAP+ activated myofibroblasts via chimeric antigen receptor T cells · 0 trials, 1 therapy
- Dual integrin inhibitor — blocks TGF-β activation at source via αvβ6/αvβ1 · 0 trials, 1 therapy
- Emulate Bio platform screens drug combinations in hours vs months · 0 trials, 1 therapy
- Engineered dendritic cells train immune system to clear fibrotic cells — promotes regulatory T-cell responses · 0 trials, 1 therapy
- Epigenetically unlocks fibroblasts from myofibroblast state · 0 trials, 1 therapy
- EV cargo (miR-29, let-7d) delivers anti-fibrotic miRNA without cell engraftment risk · 0 trials, 1 therapy
- First-in-class TNIK kinase inhibitor — blocks TRAF2/NCK-interacting kinase driving fibrosis and inflammation · 0 trials, 1 therapy
- Galectin-3 Inhibition · 1 trial
- GLP-1 receptor agonists (semaglutide/liraglutide) show anti-fibrotic + anti-inflammatory effects across organs · 0 trials, 1 therapy
- Inhaled galectin-3 inhibitor blocks fibroblast activation and TGF-β release · 0 trials, 1 therapy
- Inhaled integrin αvβ6 inhibitor — targets TGF-β activation on AEC2s · 0 trials, 1 therapy
- Inhaled LNP-mRNA OSK resets epigenetic age of AEC2s — treats root cause · 0 trials, 1 therapy
- Integrin avb6/b1 · 1 trial
- Lipid nanoparticle platform delivers therapeutic mRNA specifically to lung epithelium · 0 trials, 1 therapy
- LNP-mRNA IRF4/STAT6/KLF4 forces pro-regenerative macrophage state · 0 trials, 1 therapy
- LPA1 Antagonist · 1 trial
- LPA1 receptor antagonist — blocks lysophosphatidic acid pro-fibrotic signaling · 0 trials, 1 therapy
- ML system connecting mechanisms across IPF, regeneration, aging, cancer fields · 0 trials, 1 therapy
- mTOR inhibition reduces cellular senescence, autophagy dysfunction, and fibroblast proliferation in lung · 0 trials, 1 therapy
- Novel Therapy · 1 trial
- Parallel Multi-scale Feature Fusion Network classifies ILD patterns from CT with 97.6% accuracy · 0 trials, 1 therapy
- PPAR-y agonist + FGF10 restores AEC2 metabolic support niche · 0 trials, 1 therapy
- Prime Editing · 1 trial
- Prostacyclin analog — vasodilation + anti-fibrotic + anti-proliferative in pulmonary vasculature and parenchyma · 0 trials, 1 therapy
- R-spondin 3 expands AEC2 stem cell pool via WNT pathway · 0 trials, 1 therapy
- Reduces cytoskeletal tension, reverses myofibroblast — breaks ECM stiffness loop · 0 trials, 1 therapy
- Restores NAD+ levels depleted in aging lungs — supports sirtuin-mediated DNA repair and mitochondrial function · 0 trials, 1 therapy
- ROCK Inhibition · 1 trial
- Selective PDE4B inhibitor — elevates cAMP, suppresses pro-inflammatory cytokines and fibroblast activation · 0 trials, 1 therapy
- Senolytic — clears p16+/p21+ senescent cells, reduces SASP · 0 trials, 1 therapy
- Sequential: D+Q clears senescent cells, RSPO3 expands AEC2 pool · 0 trials, 1 therapy
- Target LAMB3+/KRT17+ aberrant cells — remove pro-fibrotic signal source · 0 trials, 1 therapy
- TGF-b Trap · 1 trial
- TNIK Inhibition (AI-discovered) · 1 trial
- WNT/AEC2 Expansion · 1 trial
Medical disclaimer. Mechanism summaries are for research context only and are not medical advice.